These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 8813576

  • 21. Dopamine D3 receptors are not involved in the induction of c-fos mRNA by neuroleptic drugs: comparison of the dopamine D3 receptor antagonist GR103691 with typical and atypical neuroleptics.
    Hurley MJ, Stubbs CM, Jenner P, Marsden CD.
    Eur J Pharmacol; 1996 Dec 30; 318(2-3):283-93. PubMed ID: 9016916
    [Abstract] [Full Text] [Related]

  • 22. Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatal subregions.
    Merchant KM, Dobie DJ, Filloux FM, Totzke M, Aravagiri M, Dorsa DM.
    J Pharmacol Exp Ther; 1994 Oct 30; 271(1):460-71. PubMed ID: 7965747
    [Abstract] [Full Text] [Related]

  • 23. Effects of serotonergic agents on the up-regulation of dopamine D2 receptors induced by haloperidol in rat striatum.
    Ishikane T, Kusumi I, Matsubara R, Matsubara S, Koyama T.
    Eur J Pharmacol; 1997 Feb 26; 321(2):163-9. PubMed ID: 9063684
    [Abstract] [Full Text] [Related]

  • 24. L-type calcium channel blockade on haloperidol-induced c-Fos expression in the striatum.
    Lee J, Rushlow WJ, Rajakumar N.
    Neuroscience; 2007 Nov 09; 149(3):602-16. PubMed ID: 17913375
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of perospirone (SM-9018), a novel serotonin-2 and dopamine-2 receptor antagonist, and other antipsychotics in the conditioned fear stress-induced freezing behavior model in rats.
    Ishida-Tokuda K, Ohno Y, Sakamoto H, Ishibashi T, Wakabayashi J, Tojima R, Morita T, Nakamura M.
    Jpn J Pharmacol; 1996 Oct 09; 72(2):119-26. PubMed ID: 8912913
    [Abstract] [Full Text] [Related]

  • 26. Effect of amperozide on rat cortical 5-HT2 and striatal and limbic dopamine D2 receptor occupancy: implications for antipsychotic action.
    Meltzer HY, Zhang Y, Stockmeier CA.
    Eur J Pharmacol; 1992 May 27; 216(1):67-71. PubMed ID: 1388121
    [Abstract] [Full Text] [Related]

  • 27. Involvement of adenosine A2A receptors in the induction of c-fos expression by clozapine and haloperidol.
    Pinna A, Wardas J, Cozzolino A, Morelli M.
    Neuropsychopharmacology; 1999 Jan 27; 20(1):44-51. PubMed ID: 9885784
    [Abstract] [Full Text] [Related]

  • 28. Induction of c-fos mRNA expression in rat striatum by neuroleptic drugs.
    Miller JC.
    J Neurochem; 1990 Apr 27; 54(4):1453-5. PubMed ID: 1690271
    [Abstract] [Full Text] [Related]

  • 29. Effects of chronic treatments with SM-9018, a potential atypical neuroleptic, on behavioral dopaminergic and serotonergic sensitivities in rats.
    Ohno Y, Ishida K, Ishibashi T, Ikeda K, Kato T, Nakamura M.
    Gen Pharmacol; 1995 May 27; 26(3):489-94. PubMed ID: 7789721
    [Abstract] [Full Text] [Related]

  • 30. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
    Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Kumagai T, Nakazato A, Nagamine M, Yamaguchi K, Tomisawa K.
    Br J Pharmacol; 1997 Jun 27; 121(3):515-25. PubMed ID: 9179395
    [Abstract] [Full Text] [Related]

  • 31. Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist.
    Ohno Y, Okano M, Imaki J, Tatara A, Okumura T, Shimizu S.
    Pharmacol Biochem Behav; 2010 Aug 27; 96(2):175-80. PubMed ID: 20460137
    [Abstract] [Full Text] [Related]

  • 32. C-fos mediates antipsychotic-induced neurotensin gene expression in the rodent striatum.
    Robertson GS, Tetzlaff W, Bedard A, St-Jean M, Wigle N.
    Neuroscience; 1995 Jul 27; 67(2):325-44. PubMed ID: 7675173
    [Abstract] [Full Text] [Related]

  • 33. Effects of risperidone and haloperidol on tachykinin and opioid precursor peptide mRNA levels in the caudate-putamen and nucleus accumbens of the rat.
    Mijnster MJ, Schotte A, Docter GJ, Voorn P.
    Synapse; 1998 Apr 27; 28(4):302-12. PubMed ID: 9517839
    [Abstract] [Full Text] [Related]

  • 34. Clozapine antagonizes the induction of striatal Fos expression by typical neuroleptics.
    Wirtshafter D.
    Eur J Pharmacol; 1998 Oct 09; 358(3):R1-3. PubMed ID: 9822897
    [Abstract] [Full Text] [Related]

  • 35. In vivo occupation of dopamine D1, D2 and serotonin2A receptors by novel antipsychotic drug, SM-9018 and its metabolite, in rat brain.
    Takahashi Y, Kusumi I, Ishikane T, Koyama T.
    J Neural Transm (Vienna); 1998 Oct 09; 105(2-3):181-91. PubMed ID: 9660096
    [Abstract] [Full Text] [Related]

  • 36. Phenotypic characterization of neuroleptic-sensitive neurons in the forebrain: contrasting targets of haloperidol and clozapine.
    Guo N, Vincent SR, Fibiger HC.
    Neuropsychopharmacology; 1998 Aug 09; 19(2):133-45. PubMed ID: 9629567
    [Abstract] [Full Text] [Related]

  • 37. Regional differences in the ability of caffeine to affect haloperidol-induced striatal c-fos mRNA expression in the rat.
    Svenningsson P, Nergårdh R, Fredholm BB.
    Neuropharmacology; 1998 Aug 09; 37(3):331-7. PubMed ID: 9681931
    [Abstract] [Full Text] [Related]

  • 38. Effects of tandospirone, a 5-HT1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice.
    Ohno Y, Shimizu S, Imaki J.
    J Pharmacol Sci; 2009 Apr 09; 109(4):593-9. PubMed ID: 19352073
    [Abstract] [Full Text] [Related]

  • 39. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ, Gobert A, Newman-Tancredi A, Audinot V, Lejeune F, Rivet JM, Cussac D, Nicolas JP, Muller O, Lavielle G.
    J Pharmacol Exp Ther; 1998 Sep 09; 286(3):1341-55. PubMed ID: 9732398
    [Abstract] [Full Text] [Related]

  • 40. 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy.
    Prinssen EP, Colpaert FC, Koek W.
    Eur J Pharmacol; 2002 Oct 25; 453(2-3):217-21. PubMed ID: 12398907
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.